World Health Organization Raises Warning Over Severe Scarcity of Obesity Jabs

Fewer than a tenth of patients that would benefit from weight-loss injections including Wegovy can access them, caution the global health agency as it publishes its initial advice on the medications.

With more than one billion individuals worldwide currently obese, it is calling for increased and just access to this class of drugs.

Based on forecasts, more than two billion could be obese by 2030 if no action is taken.

"The latest guidance affirms that obesity is a chronic disease that can be treated with holistic and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are significant obstacles to broad availability to the treatments that can aid individuals in losing considerable weight, explains the body.

GLP-1 Therapy Scarcity

Despite the present most favorable scenario, the manufacturing of such drugs might only reach around 100 million people – under 10% of those who need them, per the WHO.

The guideline urges countries and companies to increase access, through strategies including voluntary licensing.

A patent on semaglutide – the main ingredient of a leading brand – is scheduled to end in several nations in 2026.

How Weight-Loss Jabs Function

The injections replicate a natural hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so people eat less.

Patients usually see weight reduction in the initial weeks of commencing the weekly injections.

Evidence indicates patients may put most of the weight back on a year later of discontinuing the drug, because their normal food cravings return.

Being carrying excess weight raises your likelihood for experiencing diseases, like type 2 diabetes, heart disease, stroke, and some malignancies.

Obesity concerns people in all nations and was associated with millions of deaths worldwide in 2024, according to the health agency.